Heart Failure

VoluMetrix, a biotech startup focused on vital monitoring, announced the FDA granted its venous waveform monitoring device a breakthrough device designation.

The American College of Cardiology and cliexa unveiled a remote CV health monitoring platform, according to a press release.

Elevated baseline high-sensitivity cardiac troponin T was associated with CV death and HF hospitalization in patients from the VICTORIA trial, according to a presentation at the American College of Cardiology Scientific Session.

In patients with HF from the VICTORIA trial, those with CAD had worse outcomes, according to a presentation at the American College of Cardiology Scientific Session.

Patients with peripheral artery disease and HF have higher rates of CAD and elevated risk for adverse CV events and mortality compared with patients with PAD but no HF, researchers reported.

The FDA and Medtronic alerted health care providers to no longer implant patients with end-stage HF with a ventricular assist device system due to the frequency of neurological adverse events and mortality.

In patients from the REDUCE-IT trial assigned icosapent ethyl, those who achieved high or moderate levels of eicosapentaenoic acid had better HF outcomes compared with those who achieved low levels, researchers reported.

Lowering systolic BP to less than 120 mm Hg significantly reduced risk for MI, HF and CVD death compared with a systolic BP of less than 140 mm Hg, according to the final results of the SPRINT trial.

Excess pericardial fat volume was associated with higher risk for HF, especially HF with preserved ejection fraction, researchers reported.

The American College of Cardiology recently held its annual meeting. Healio’s coverage of the virtual conference made up the top stories in cardiology last week.